Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus

Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann NY Acad Sci. 2010;1183:267–87.

Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012;2012:494356.

Mahler M, Dervieux T. Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies. Ann Rheum Dis. 2014;73:e36.

Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17–23.

Copple SS, Giles SR, Jaskowski TD, Gardiner AE, Wilson AM, Hill HR. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. Am J Clin Pathol. 2012;137:825–30.

Van BM, Van CC, Bossuyt X, et al. Current practices in antinuclear antibody testing: results from the Belgian External Quality Assessment Scheme. Clin Chem Lab Med. 2009;47:102–8.

Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum. 1999;42:455–64.

Peterson LK, Wells D, Shaw L, Velez MG, Harbeck R, Dragone LL. Novel method for quantitative ANA measurement using near-infrared imaging. J Immunol Methods. 2009;349:1–8.

Sack U, Conrad K, Csernok E, et al. Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann NY Acad Sci. 2009;1173:166–73.

Burlingame RW, Peebles C. Detection of Antibodies. In: Pollard KM, editor. Autoantibodies and autoimmunity: molecular mechanisms in health and disease. Weinheim: Wiley-VCH; 2006. p. 159–88.

Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53:424–32.

Fenger M, Wiik A, Hoier-Madsen M, et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. Clin Chem. 2004;50:2141–7.

Bradwell AR, Hughes RG, Karim AR. Immunofluorescent antinuclear antibody tests. In: Detrick B, Hamilton RG, Folds JD, editors. Manual of clinical laboratory immunology. 7th ed. Washington: ASM press; 2006. p. 995–1006.

Emlen W, O’Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997;40:1612–8.

Egerer K, Roggenbuck D, Hiemann R, et al. Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther. 2010;12:R40.

Hiemann R, Buttner T, Krieger T, Roggenbuck D, Sack U, Conrad K. Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmun Rev. 2009;9:17–22.

Willitzki A, Hiemann R, Peters V, et al. New platform technology for comprehensive serological diagnostics of autoimmune diseases. Clin Dev Immunol. 2012;2012:284740.

Voigt J, Krause C, Rohwader E, et al. Automated indirect immunofluorescence evaluation of antinuclear autoantibodies on HEp-2 cells. Clin Dev Immunol. 2012;2012:651058.

Roggenbuck D, Hiemann R, Schierack P, Reinhold D, Conrad K. Digital immunofluorescence enables automated detection of antinuclear antibody endpoint titers avoiding serial dilution. Clin Chem Lab Med 2014;52:e9–11.

Bonroy C, Verfaillie C, Smith V, et al. Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clin Chem Lab Med. 2013;51:1771–9.

Bossuyt X, Cooreman S, De BH, et al. Detection of antinuclear antibodies by automated indirect immunofluorescence analysis. Clin Chim Acta. 2013;415:101–6.

Roggenbuck D, Hiemann R, Bogdanos D, Reinhold D, Conrad K. Standardization of automated interpretation of immunofluorescence tests. Clin Chim Acta. 2013;421:168–9.

Tonuttia E, Bassetti D, Piazza A, et al. Diagnostic accuracy of ELISA methods as an alternative screening test to indirect immunofluorescence for the detection of antinuclear antibodies. Evaluation of five commercial kits. Autoimmunity. 2004;37:171–6.

Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69:1420–2.

Bossuyt X, Fieuws S. Detection of antinuclear antibodies: added value of solid phase assay? Ann Rheum Dis. 2014;73:e10.

Shovman O, Gilburd B, Barzilai O, et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann NY Acad Sci. 2005;1050:380–8.

Shovman O, Gilburd B, Zandman-Goddard G, Yehiely A, Langevitz P, Shoenfeld Y. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity. 2005;38:105–9.

Mahler M, Fritzler MJ, Bluthner M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther. 2005;7:R19–29.

Mahler M, Radice A, Yang W, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012;413:719–26.

Bentow C, Swart A, Wu J, et al. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta. 2013;424:141–7.

Fijorek K, Fijorek D, Wisniowska B, Polak S. BDTcomparator: a program for comparing binary classifiers. Bioinformatics. 2011;27:3439–40.

Nofuentes JA, Del Castillo JD. Comparison of the likelihood ratios of two binary diagnostic tests in paired designs. Stat Med. 2007;26:4179–201.

Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37:360–3.

Infantino M, Bentow C, Seaman A, et al. Highlights on Novel Technologies for the Detection of Antibodies to Ro60, Ro52, and SS-B. Clin Dev Immunol. 2013;2013:978202.

Bentow C, Seaman A, Swart A, Shikhman A, Goodman N, Mahler M. Evaluation of a novel chemiluminescent assay (QUANTA Flash® CTD Screen Plus) for the rapid detection of autoantibodies in systemic autoimmune rheumatic diseases. In: 11th symposium on autoantibodies, Dresden, Germany 2013.

Parker JC, Bunn CC. Sensitivity of the Phadia EliA connective tissue disease screen for less common disease-specific autoantibodies. J Clin Pathol. 2011;64:631–3.

De Op, Beeck K, Vermeersch P, Verschueren P, et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev. 2011;10:801–8.

Mahler M, Gascon C, Patel S, et al. Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther. 2013;15:R50.

Mahler M, Satoh M, Hudson M, et al. Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. J Rheumatol. 2014;41:1334–43.

Bossuyt X. Antinuclear antibody detection by automated indirect immunofluorescence: opportunities for value added reporting. In: 9th international congress on autoimmunity, Nice, France 2014.

Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:315179.

Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A. Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med. 2014;12:38.

Copple SS, Jaskowski TD, Giles R, Hill HR. Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA View compared to manual microscopy. J Immunol Res. 2014;2014:149316.